Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery

• Verfasst von: Mohamed, Sherif A. [VerfasserIn]
• Verfasst von: Barlemann, Alina [VerfasserIn]
• Verfasst von: Wagner, Verena [VerfasserIn]
• Verfasst von: Nonnenmacher, Tobias [VerfasserIn]
• Verfasst von: Güttlein, Michelle [VerfasserIn]
• Verfasst von: Hackert, Thilo [VerfasserIn]
• Verfasst von: Loos, Martin [VerfasserIn]
• Verfasst von: Gaida, Matthias M. [VerfasserIn]
• Verfasst von: Kauczor, Hans-Ulrich [VerfasserIn]
• Verfasst von: Klauß, Miriam [VerfasserIn]
• Verfasst von: Mayer, Philipp [VerfasserIn]
• Titel: Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery
• Verf.angabe: Sherif A. Mohamed, Alina Barlemann, Verena Steinle, Tobias Nonnenmacher, Michelle Güttlein, Thilo Hackert, Martin Loos, Matthias M. Gaida, Hans-Ulrich Kauczor, Miriam Klauss & Philipp Mayer
• E-Jahr: 2024
• Jahr: 26 August 2024
• Umfang: 12 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 08.10.2024
• Titel Quelle: Enthalten in: Scientific reports
• Ort Quelle: [London] : Springer Nature, 2011
• Jahr Quelle: 2024
• Band/Heft Quelle: 14(2024), Artikel-ID 19783, Seite 1-12
• ISSN Quelle: 2045-2322
• DOI: doi:10.1038/s41598-024-70441-3
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cancer imaging
• Sach-SW: Pancreatic cancer
• K10plus-PPN: 1905106807

Abstract

The prognosis of pancreatic cancer (PDAC) after tumor resection remains poor, mostly due to a high but variable risk of recurrence. A promising tool for improved prognostication is the quantification of CT tumor enhancement. For this, various enhancement formulas have been used in previous studies. However, a systematic comparison of these formulas is lacking. In the present study, we applied twenty-three previously published CT enhancement formulas to our cohort of 92 PDAC patients who underwent upfront surgery. We identified seven formulas that could reliably predict tumor recurrence. Using these formulas, weak tumor enhancement was associated with tumor recurrence at one and two years after surgery (p ≤ 0.030). Enhancement was inversely associated with adverse clinicopathological features. Low enhancement values were predictive of a high recurrence risk (Hazard Ratio ≥ 1.659, p ≤ 0.028, Cox regression) and a short time to recurrence (TTR) (p ≤ 0.027, log-rank test). Some formulas were independent predictors of TTR in multivariate models. Strikingly, almost all of the best-performing formulas measure solely tumor tissue, suggesting that normalization to non-tumor structures might be unnecessary. Among the top performers were also the absolute arterial/portal venous tumor attenuation values. These can be easily implemented in clinical practice for better recurrence prediction, thus potentially improving patient management.